ReviewAnnals of surgical oncology2025
The Landmark Series: Hepatic Arterial Infusion Pump Chemotherapy for Colorectal Liver Metastases and Intrahepatic Cholangiocarcinoma.
Review in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chromosomal instability induced by CRISPR/Cas9: implications for pancreatic cancer therapy.The Journal of clinical investigation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatic arterial infusion pump (HAIP) chemotherapy delivers continuous locoregional chemotherapy directly to the liver, maximizing intrahepatic tumor exposure while minimizing systemic toxicity. Originally developed at Memorial Sloan Kettering Cancer Center, HAIP chemotherapy with floxuridine is increasingly used for colorectal liver metastases (CRLM) and intrahepatic cholangiocarcinoma (iCCA). This paper presents a review of phase II and III trials, retrospective studies, and ongoing prospective trials was conducted to evaluate the efficacy of HAIP floxuridine combined with systemic regimens in patients with unresectable and resectable liver-confined CRLM and iCCA.
resultsIn unresectable CRLM, HAIP yields conversion rates between 20 to 55% resulting in 5-year overall survival (OS) up to 50%. In the setting of adjuvant HAIP after resection of CRLM, a first large randomized controlled trial (RCT) showed a 2-year OS of 86% compared with 72% in patients with adjuvant systemic therapy alone. In a second RCT, the median OS was 47 months after HAIP with systemic chemotherapy versus 34 months without adjuvant chemotherapy. For unresectable iCCA, studies have found a response rate of 21% and a 3-year OS of 3% following systemic therapy alone (ABC trials), while outcomes for patients receiving HAIP chemotherapy combined with systemic therapy have included response rates up to 58% and 3-year OS up to 43%.
conclusionHepatic arterial infusion pump floxuridine is an effective locoregional treatment that improves survival in patients with liver-confined CRLM and iCCA. Confirmation from ongoing RCTs is awaited to define its role alongside evolving systemic therapies.
Identifiers
40940601What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.